Amphastar Pharmaceuticals (AMPH) FY2021 results: revenue $438 million, up 25.1% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $438 million for fiscal 2021, the year ended 31 December 2021, up 25.1% on the year before. Net income was $62 million, up 4327.4%, and diluted earnings per share $1.25. The figures are the company's own, from the 10-K it filed with the SEC on 11 March 2022.
Revenue
$438 million
+25.1% on the year
FY2014FY2021
Operating margin
16.0%
3.1% a year earlier
FY2014FY2021
Net income
$62 million
+4,327.4% on the year
FY2014FY2021
Diluted EPS
$1.25
+4,066.7% on the year
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
98.0
57.3
41.8
+71.1%
Capital expenditure
27.5
33.9
41.6
-18.9%
Free cash flow
70.5
23.4
0.2
+201.3%
Free cash flow margin
16.1%
6.7%
0.1%
Cash from investing
-28.7
-36.4
-50.5
Cash from financing
-37.0
-2.2
-3.8
Depreciation and amortisation
10.2
9.0
7.1
+13.2%
Share-based compensation
18.7
20.5
17.3
-8.8%
Buybacks
28.9
24.4
22.3
+18.2%
Diluted shares, weighted
50m
49m
50m
+1.3%
Shares outstanding at period end
48m
47m
47m
+0.5%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
446
402
381
+10.7%
Non-controlling interest
n/a
46.4
46.2
Debt
78.2
45.9
46.3
+70.3%
Operating lease liabilities
24.7
17.5
16.3
+41.5%
Finance lease liabilities
0.4
0.6
n/a
-34.8%
Other liabilities
123
119
96.8
+3.5%
Total liabilities and equity
672
631
587
+6.4%
Fixed assets
244
260
234
-6.1%
Goodwill
3.3
3.9
3.6
-15.9%
Intangible assets
6.3
7.5
8.3
-15.0%
Investments
10.3
13.0
11.7
-20.5%
Cash and equivalents
126
92.6
73.7
+36.4%
Receivables
78.8
66.0
45.4
+19.4%
Inventory
92.8
96.8
111
-4.2%
Other assets
109
91.3
100.0
+19.7%
Total assets
672
631
587
+6.4%
10-K for the year ended 31 December 2021, filed 11 March 2022: the filing.